Download PDF
Erfahrungsheilkunde 2019; 68(03): 132-139
DOI: 10.1055/a-0898-2234
Praxis
© MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Chondroitinsulfat und Glucosamin bei Arthrose

Hugo Schurgast
Further Information

Publication History

Publication Date:
05 July 2019 (online)

    Permissions and Reprints

Zusammenfassung

Für die Behandlung der Arthrose mit den SYSADOAs (symptomatic slow-acting drugs in osteoarthritis) Chondroitinsulfat und Glucosamin (einzeln oder in Kombination) liegt mittlerweile eine gute wissenschaftliche Evidenz vor: Weniger Schmerz und Entzündung, Reduktion der Verengung des Gelenkspalts, Verbesserung der Funktionalität und Lebensqualität bei einem guten Nutzen-Risiko-Verhältnis machen Chondroitinsulfat, aber auch Glucosamin zu einem praktikablen First-Line-Treatment, insbesondere bei der Behandlung der Kniearthrose. Um diese positiven Wirkungen zu erzielen, müssen aber einige Voraussetzungen erfüllt sein: Qualität der Wirkstoffe, korrekte Dosierung und eine je nach Zielsetzung ausreichend lange Interventionsdauer (Compliance des Patienten!). Dies ist nur mit einer fachmännischen Beratung gewährleistet.

Abstract

For the treatment of arthrosis with the SYSADOAs (symptomatic slow-acting drugs in osteoarthritis) chondroitin sulfate and glucosamine (individually or in combination) there is good scientific evidence now: less pain and inflammation, reduction of joint space narrowing, improvement of functionality and quality of life with a good benefit-risk balance make chondroitin sulfate, but also glucosamine, a practicable first-line treatment, especially in the case of knee arthrosis. However, a number of conditions must be met in order to achieve these positive effects: quality of the active ingredients, correct dosage and, depending on the objective, a sufficiently long intervention period (compliance of the patient!). This is only guaranteed with professional advice.

Schlüsselwörter

Chondroitinsulfat - Glucosamin - Glucosaminsulfat - Glucosamin HCl - Arthrose

Key words

Chondroitin sulfate - glucosamine - glucosamine sulfate - glucosamine HCI - arthrosis
 

  • Literatur

  • 1 Ogata T. et al. Effects of glucosamine in patients with osteoarthritis of the knee: A systematic review and meta-analysis. Clin Rheumatol 2018; 37: 2479-2487
    CrossrefPubMedGoogle Scholar
  • 2 Reginster JY. et al. Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis 2017; 0: 1-2 doi:10.1136/annrheumdis-2017–212251
    PubMedGoogle Scholar
  • 3 Altman RD. Glucosamine therapy for knee osteoarthritis: Pharmacokinetic considerations. Expert Rev Clin Pharmacol 2009; 2: 359-371
    CrossrefPubMedGoogle Scholar
  • 4 Persiani S. et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarth Cart 2007; 15: 764-772
    CrossrefPubMedGoogle Scholar
  • 5 Runhaar J. et al. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: A systematic review and individual patient data meta-analysis from the OA trial bank. Ann Rheum Dis. 2017 DOI: doi:10.1136/annrheumdis-2017–211149
    PubMedGoogle Scholar
  • 6 Reginster JY. et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet 2001; 357 (9252) 251-256
    CrossrefPubMedGoogle Scholar
  • 7 Poolsup N. et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: A systematic review of randomized controlled trials. Ann Pharmacother 2005; 39 (06) 1080-1087
    CrossrefPubMedGoogle Scholar
  • 8 Bruyere O. et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: Results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarth Cart 2008; 16 (02) 254-260
    CrossrefPubMedGoogle Scholar
  • 9 Knapik JJ. et al. Effects of oral glucosamine sulfate on osteoarthritis-related pain and joint-space changes: Systematic review and meta-analysis. J Spec Oper Med 2018; 18 (04) 139-147
    PubMedGoogle Scholar
  • 10 Thie NM. et al. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: A randomized double-blind controlled 3 month clinical trial. J Rheumatol 2001; 28: 1347-1355
    PubMedGoogle Scholar
  • 11 Rovati LC. A large, randomized, placebo-controlled, double-blind study of glucosamine sulfate vs. piroxicam and vs. their association, on the kinetics of the symptomatic effect in knee osteoarthritis. Osteoarth Cart 1994; 2 (Suppl. 01) 56
    PubMedGoogle Scholar
  • 12 Wandel S. et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of the knee: Network meta-analysis. BMJ 2010; 341: c4675
    CrossrefPubMedGoogle Scholar
  • 13 Kahan A. et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis. Arthr Rheum 2009; 60 (02) 524-533
    CrossrefPubMedGoogle Scholar
  • 14 Simental-Mendia M. et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: A systematic review and meta-analysis of randomized placebo-controlled trials. Rheum Int 2018; 38 (08) 1413-1428
    CrossrefPubMedGoogle Scholar
  • 15 Zhu X. et al. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: A meta-analysis of randomized controlled trials. J Orthopaed Surg Res 2018; 13: 170
    PubMedGoogle Scholar
  • 16 Fransen M. et al. Glucosamine and chondroitin for knee osteoarthritis: A double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2014 DOI: doi:10.1136/annrheumdis-2013–203954
    PubMedGoogle Scholar
  • 17 Raynauld JP. et al. Long-term effect of glucosamine and chondroitin sulfate on the progression of structural changes in knee osteoarthritis: Six-year followup data from the osteoarthritis initiative. Arthritis Care Res 2016; 68 (10) 1560-1566
    PubMedGoogle Scholar
  • 18 Hochberg MC. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: A multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37-44
    CrossrefPubMedGoogle Scholar
  • 19 Provenza JR. et al. Combined glucosamine and chondroitin sulfate, one or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol. 2014 DOI: doi:10.1007/s10067–014–2757–1
    PubMedGoogle Scholar
  • 20 Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf®) and its constituents in healthy male volunteers. Osteoarth Cart 2002; 10: 768-777
    CrossrefPubMedGoogle Scholar
  • 21 Volpi N. The evolution of chondroitin sulfate. Non-animal chondroitin sulfate. Mediprint; (Rome, Italy): 2016: 1-75
    Google Scholar
  • 22 Reginster J-Y. et al. Pharmaceutical grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteorthritis: The ChONdroitin versus CElecoxib Placebo Trial (CONCEPT). Ann Rheum Dis 2017; 76: 1537-1543
    CrossrefPubMedGoogle Scholar
  • 23 Nakayama Y. et al. The effects of age and sex on chondroitin sulfates in normal synovial fluid. Arth & Rheum 2002; 46 (08) 2105-2108
    PubMedGoogle Scholar
  • 24 Morreale P. et al. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23 (08) 1385-1391
    PubMedGoogle Scholar
  • 25 Pelletier J-P. et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnestic resonance imaging: A 2-year multicentre exploratory study. Arthr Res Ther 2016; 18: 256
    CrossrefPubMedGoogle Scholar
  • 26 Pavelka K. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162 (18) 2113-2123
    CrossrefPubMedGoogle Scholar
  • 27 Lee YH. et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheum Int 2010; 30 (03) 357-363
    CrossrefPubMedGoogle Scholar
  • 28 Singh JA. et al. Chondroitin for osteoarthritis. Coch Datab Syst Rev 2015; 1 doi:10.1002/14651858.CD005614.pub2
    PubMedGoogle Scholar
  • 29 Bayliss MT. et al. Sulfation of chondroitin sulfate in human articular cartilage. J Biol Chem 1999; 274 (22) 15892-15900
    CrossrefPubMedGoogle Scholar
  • 30 Bundesinstitut für Risikobewertung(BfR). Risikobewertung von Chondroitinsulfat in Nahrungsergänzungsmitteln. Aktualisierte Stellungnahme Nr. 040/2018, 7. Dezember 2018. DOI: doi:10.17590/20181207–123833–0
    PubMedGoogle Scholar
  • 31 Fardellone P. et al. Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol J 2013; 7: 1-12
    PubMedGoogle Scholar
  • 32 Martel-Pelletier J. et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 2015; 20: 4277-4289
    CrossrefPubMedGoogle Scholar
  • 33 Tat SK. et al. Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: Relevance of purity and production process. J Rheumatol 2010; 37: 656-664
    PubMedGoogle Scholar
  • 34 Lauder RM. Chondroitin sulphate: A complex molecule with potential impacts on a wide range of biological systems. Compl Ther Med 2009; 17: 56-62
    CrossrefPubMedGoogle Scholar
  • 35 Eidgenössisches Departement des Innern. Verordnung des EDI über Nahrungsergänzungsmittel (VNem) vom 16.12.2016: 1285–1302.
    PubMedGoogle Scholar
  • 36 Honvo G. et al. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: A comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 2019 DOI: doi:10.1007/s12325–019–00921-w
    PubMedGoogle Scholar
  • 37 Altman RD. et al. Commentary: Osteoarthritis of the knee and glucosamine. Osteoarthritis and Cartilage 2006; 14: 963-966
    CrossrefPubMedGoogle Scholar
  • 38 Persiani S. et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarth Cart 2005; 13: 1041-1049
    CrossrefPubMedGoogle Scholar